One Health Approach to Vaccine Development
The One Health approach emphasizes the interconnection between human, animal, and environmental health in understanding and preventing infectious diseases. Recognizing that approximately 60% of emerging infectious diseases are zoonotic, vaccine development under this framework integrates veterinary science, human medicine, and ecological studies to reduce disease transmission at its source. Research focuses on pathogens that circulate between animals and humans, including influenza, coronaviruses, and vector-borne diseases, using surveillance data to identify hotspots and predict outbreaks. Vaccines developed with a One Health perspective aim to control infections in animal reservoirs, thereby reducing the risk of spillover into human populations. This approach also considers environmental factors such as habitat disruption, climate change, and human encroachment, which influence pathogen evolution and emergence. Collaborative initiatives bring together scientists, public health authorities, policymakers, and international organizations to harmonize vaccination strategies across species and ecosystems. One Health-driven vaccine development supports global health security, ensures efficient allocation of resources, and enhances preparedness against pandemics. By integrating veterinary, human, and environmental sciences, this approach provides a holistic and sustainable solution to infectious disease prevention, demonstrating that the health of humans is inseparable from that of animals and the environment.
Related Conference of One Health Approach to Vaccine Development
7th International conference on Vaccines, Vaccination and Immunization
10th International Conference on Vaccines, Immunology and Clinical Trials
One Health Approach to Vaccine Development Conference Speakers
Recommended Sessions
- Bioinformatics and AI in Vaccine Design
- Challenges in Vaccine Accessibility and Equity
- Clinical Vaccinology and Immunotherapy
- Emerging Infectious Diseases
- Future Directions in Vaccine Research
- Global Vaccination Strategies
- Human Microbiome and Vaccines
- Immunogenetics and Personalized Vaccines
- Immunogenetics and Personalized Vaccines
- Immunology and Immune System Innovations
- Immunology of Infectious Diseases
- Immunotherapy and Vaccines for Non-Infectious Diseases
- Immunotherapy in Cancer Treatment
- Industry and Technology Innovations
- Maternal, Neonatal, and Geriatric Immunization
- Microbiome-Targeted Vaccines
- Nanotechnology and Advanced Delivery Systems
- Nanotechnology in Vaccine Delivery
- Next-Generation Vaccine Platforms
- Novel Vaccine Platforms: mRNA, DNA, and Viral Vectors
- One Health Approach to Vaccine Development
- Pandemic Preparedness and Response
- Public Health and Global Immunization
- The Economics of Vaccination
- Vaccine Hesitancy and Public Trust
- Vaccine Production and Global Supply Chains
- Vaccine Research and Development
- Vaccine Safety and Adverse Event Monitoring
- Vaccine-Induced Immunity and Duration of Protection
- Vaccine Safety, Pharmacovigilance, and Adverse Event Monitoring
Related Journals
Are you interested in
- Adaptive Immunity and Immune Memory Formation - WORLD VACCINES 2026 (France)
- Adjuvants and Immune Modulation Strategies - WORLD VACCINES 2026 (France)
- Adverse reactions to the vaccination - Vaccines Congress-2026 (UK)
- Animal & Plant Derived Vaccines - Vaccines-Immunization-2026 (France)
- Animal Models & Clinical Trials - Vaccines-Immunization-2026 (France)
- Antibodies: Engineering & Therapeutics - Vaccines-Immunization-2026 (France)
- Antinatal vaccinations - Vaccines Congress-2026 (UK)
- Bacterial Vaccines and Toxoid Development - WORLD VACCINES 2026 (France)
- Bioinformatics and AI in Vaccine Design - Vaccine Immunology 2026 (Canada)
- Cancer, Malaria & TB Vaccines - Vaccines-Immunization-2026 (France)
- Cellular Immunology & Latest Innovations - Vaccines-Immunization-2026 (France)
- Challenges in Vaccine Accessibility and Equity - Vaccine Immunology 2026 (Canada)
- Clinical Vaccinology and Immunotherapy - Vaccine Immunology 2026 (Canada)
- Combination & Conjugate Vaccines - Vaccines-Immunization-2026 (France)
- Computational Immunology and Vaccine Modeling - WORLD VACCINES 2026 (France)
- Conjugated and combination vaccinations - Vaccines Congress-2026 (UK)
- Creation and development of vaccines - Vaccines Congress-2026 (UK)
- Current Research & Future Challenges - Vaccines-Immunization-2026 (France)
- DNA & Synthetic Vaccines - Vaccines-Immunization-2026 (France)
- DNA, RNA & SYNTHETIC VACCINES - Vaccines Congress-2026 (UK)
- Emerging and Re-Emerging Infectious Diseases - WORLD VACCINES 2026 (France)
- Emerging Infectious Diseases - Vaccine Immunology 2026 (Canada)
- Fish & Poultry Vaccines - Vaccines-Immunization-2026 (France)
- Future Directions in Vaccine Research - Vaccine Immunology 2026 (Canada)
- Future Directions in Vaccines and Immunology - WORLD VACCINES 2026 (France)
- Geriatric Immunization - Vaccines-Immunization-2026 (France)
- Global Vaccination Strategies - Vaccine Immunology 2026 (Canada)
- HIV , Malaria & TB vaccines - Vaccines Congress-2026 (UK)
- HIV Vaccines - Vaccines-Immunization-2026 (France)
- Human Microbiome and Vaccines - Vaccine Immunology 2026 (Canada)
- Immunogenetics and Host Immune Variability - WORLD VACCINES 2026 (France)
- Immunogenetics and Personalized Vaccines - Vaccine Immunology 2026 (Canada)
- Immunogenetics and Personalized Vaccines - Vaccine Immunology 2026 (Canada)
- Immunology and Immune System Innovations - Vaccine Immunology 2026 (Canada)
- Immunology of Infectious Diseases - Vaccine Immunology 2026 (Canada)
- Immunopathology and Vaccine Safety - WORLD VACCINES 2026 (France)
- Immunotherapy and Vaccines for Non-Infectious Diseases - Vaccine Immunology 2026 (Canada)
- Immunotherapy in Cancer Treatment - Vaccine Immunology 2026 (Canada)
- Industry and Technology Innovations - Vaccine Immunology 2026 (Canada)
- Innate Immune Responses in Vaccination - WORLD VACCINES 2026 (France)
- Maternal, Neonatal, and Geriatric Immunization - Vaccine Immunology 2026 (Canada)
- Microbiome-Targeted Vaccines - Vaccine Immunology 2026 (Canada)
- mRNA Vaccines and Nucleic Acid Platforms - WORLD VACCINES 2026 (France)
- Mucosal Immunity and Alternative Vaccine Routes - WORLD VACCINES 2026 (France)
- Nanotechnology and Advanced Delivery Systems - Vaccine Immunology 2026 (Canada)
- Nanotechnology in Vaccine Delivery - Vaccine Immunology 2026 (Canada)
- Next-Generation Vaccine Platforms - Vaccine Immunology 2026 (Canada)
- Novel Vaccine Platforms: mRNA, DNA, and Viral Vectors - Vaccine Immunology 2026 (Canada)
- One Health Approach to Vaccine Development - Vaccine Immunology 2026 (Canada)
- Paediatric Vaccination - Vaccines-Immunization-2026 (France)
- Pandemic Preparedness and Response - Vaccine Immunology 2026 (Canada)
- Pediatric and Geriatric Immunization Strategies - WORLD VACCINES 2026 (France)
- Public Health and Global Immunization - Vaccine Immunology 2026 (Canada)
- rDNA technology in vaccine development - Vaccines Congress-2026 (UK)
- Recent advances in vaccine development - Vaccines Congress-2026 (UK)
- Regulatory Science and Vaccine Approval Pathways - WORLD VACCINES 2026 (France)
- The COVID-19 vaccine's next-generation RNA platforms and mRNA - Vaccines Congress-2026 (UK)
- The Economics of Vaccination - Vaccine Immunology 2026 (Canada)
- Toxoid vaccination - Vaccines Congress-2026 (UK)
- Translational Vaccinology from Research to Practice - WORLD VACCINES 2026 (France)
- Travel & Edible Vaccines - Vaccines-Immunization-2026 (France)
- Vaccine and Vaccination - Vaccines Congress-2026 (UK)
- Vaccine Biomarkers and Immune Correlates - WORLD VACCINES 2026 (France)
- Vaccine Delivery Systems and Targeting Approaches - WORLD VACCINES 2026 (France)
- Vaccine Design and Antigen Engineering - WORLD VACCINES 2026 (France)
- Vaccine efficiency and well-being - Vaccines Congress-2026 (UK)
- Vaccine for infectious illnesses in humans - Vaccines Congress-2026 (UK)
- Vaccine Hesitancy and Public Trust - Vaccine Immunology 2026 (Canada)
- Vaccine Manufacturing and Scale-Up Technologies - WORLD VACCINES 2026 (France)
- Vaccine manufacturing technologies - Vaccines Congress-2026 (UK)
- Vaccine Production & Development - Vaccines-Immunization-2026 (France)
- Vaccine Production and Global Supply Chains - Vaccine Immunology 2026 (Canada)
- Vaccine Research and Clinical trials - Vaccines Congress-2026 (UK)
- Vaccine Research and Development - Vaccine Immunology 2026 (Canada)
- Vaccine Safety and Adverse Event Monitoring - Vaccine Immunology 2026 (Canada)
- Vaccine Safety, Pharmacovigilance, and Adverse Event Monitoring - Vaccine Immunology 2026 (Canada)
- Vaccine-Induced Cellular Immunity - WORLD VACCINES 2026 (France)
- Vaccine-Induced Immunity and Duration of Protection - Vaccine Immunology 2026 (Canada)
- Vaccines - Vaccines-Immunization-2026 (France)
- Vaccines & Autism - Vaccines-Immunization-2026 (France)
- Vaccines against Drugs - Vaccines-Immunization-2026 (France)
- Vaccines against Infectious Diseases - Vaccines-Immunization-2026 (France)
- Vaccines against non-traditional illnesses - Vaccines Congress-2026 (UK)
- VACCINES FOR CANCER - Vaccines Congress-2026 (UK)
- Vaccines for Immune Mediated Diseases - Vaccines-Immunization-2026 (France)
- Vaccines for Pregnant Women & Neonates - Vaccines-Immunization-2026 (France)
- Vaccines for Unconventional Diseases - Vaccines-Immunization-2026 (France)
- Vectors, Adjuvants & Delivery Systems - Vaccines-Immunization-2026 (France)
- Viral Vaccine Platforms and Vector Technologies - WORLD VACCINES 2026 (France)
- Zika Virus vaccines - Vaccines Congress-2026 (UK)

